Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory Registration Study
CEL-SCI Corporation (NYSE American: CVM) today announced that a manuscript highlighting the latest findings from its Phase 3 study titled "A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role of Tumor PD-L1 Expression," has been accepted for publication in Oral Oncology, one of the world's leading peer-reviewed journals dedicated to head and neck cancer research and treatment.
The manuscript, authored by Eyal Talor, Ph.D. (CEL-SCI Chief Scientific Officer, the developer of Multikine) and colleagues, is based on data from CEL-SCI's landmark Phase 3 IT-MATTERS clinical trial evaluating Multikine® (Leukocyte Interleukin, Injection)* in the treatment of newly diagnosed treatment naïve, resectable, locally advanced head and neck cancer patients. In accordance with the journal's publication policies, CEL-SCI will disclose the scientific findings following publication in Oral Oncology.
